Dermira (NASDAQ:DERM) Trading 15.4% Higher

Share on StockTwits

Dermira Inc (NASDAQ:DERM)’s share price traded up 15.4% on Monday . The company traded as high as $9.26 and last traded at $9.09, 1,664,550 shares changed hands during mid-day trading. An increase of 38% from the average session volume of 1,209,927 shares. The stock had previously closed at $7.88.

Several analysts have issued reports on DERM shares. Leerink Swann decreased their price objective on shares of Dermira from $23.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Zacks Investment Research upgraded Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 target price for the company in a research report on Wednesday, October 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Dermira in a research note on Friday, October 18th. Finally, BidaskClub upgraded Dermira from a “strong sell” rating to a “sell” rating in a report on Saturday, October 19th. Two analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $16.80.

The stock has a market capitalization of $429.63 million, a PE ratio of -1.73 and a beta of 1.37. The company has a quick ratio of 6.63, a current ratio of 7.03 and a debt-to-equity ratio of 25.08. The stock’s 50 day moving average price is $7.69 and its 200-day moving average price is $8.21.

Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.40) by $0.34. The firm had revenue of $11.53 million for the quarter, compared to analysts’ expectations of $11.07 million. Dermira had a negative net margin of 256.08% and a negative return on equity of 583.07%. As a group, sell-side analysts predict that Dermira Inc will post -4.21 earnings per share for the current fiscal year.

In other Dermira news, Director Matthew K. Fust sold 6,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $8.77, for a total value of $52,620.00. Following the completion of the sale, the director now directly owns 11,051 shares of the company’s stock, valued at approximately $96,917.27. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 12.40% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Metropolitan Life Insurance Co NY increased its holdings in Dermira by 57.4% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 16,847 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 6,141 shares during the period. Millennium Management LLC increased its stake in shares of Dermira by 747.5% during the third quarter. Millennium Management LLC now owns 409,129 shares of the biopharmaceutical company’s stock valued at $2,614,000 after buying an additional 360,852 shares during the period. Squarepoint Ops LLC increased its stake in shares of Dermira by 12.2% during the third quarter. Squarepoint Ops LLC now owns 178,732 shares of the biopharmaceutical company’s stock valued at $1,142,000 after buying an additional 19,480 shares during the period. Great Point Partners LLC increased its stake in shares of Dermira by 68.8% during the third quarter. Great Point Partners LLC now owns 2,621,333 shares of the biopharmaceutical company’s stock valued at $16,750,000 after buying an additional 1,068,433 shares during the period. Finally, California State Teachers Retirement System raised its holdings in shares of Dermira by 2.6% in the third quarter. California State Teachers Retirement System now owns 73,649 shares of the biopharmaceutical company’s stock valued at $471,000 after acquiring an additional 1,857 shares in the last quarter. Institutional investors own 94.75% of the company’s stock.

About Dermira (NASDAQ:DERM)

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Featured Story: Why is the Consumer Price Index (CPI) important?

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.